Strontium89 (Strontium Chloride Sr-89 injection), a radiopharmaceutical indicated for the relief of bone pain in patients with painful skeletal metastases, has been made available by Q BioMed.
A recent report published in the New England Journal of Medicine describes the case of a 57-year-old male patient who developed skin hyperpigmentation following chemotherapy that included fluorouracil.
The FDA has granted accelerated approval to Tazverik™ (tazemetostat tablets; Epizyme) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Lorcaserin may potentially increase the risk of cancer, according to results from a clinical trial assessing the safety of the weight loss agent.
The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
A biosimilar is a biological product that is approved based on data demonstrating high similarity to an FDA-approved biological product (reference product).
The FDA has approved Calquence (acalabrutinib; AstraZeneca) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
Truxima (rituximab-abbs; Teva and Celltrion), a biosimilar to Rituxan (rituximab; Genentech) will be available in the US the week of November 11, 2019 for the treatment of adults with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
In patients with rheumatologic diseases, treatment with interleukin inhibitors may increase the risk of serious infections, opportunistic infections, and cancer.
Cinvanti injectable emulsion can be administered as a 2-minute intravenous injection or 30-minute intravenous infusion.
